145 related articles for article (PubMed ID: 36059090)
21. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
22. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas].
He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094
[No Abstract] [Full Text] [Related]
23. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC.
Zhao CC; Jiao Y; Zhang YY; Ning J; Zhang YR; Xu J; Wei W; Kang-Sheng G
Cell Death Dis; 2019 Mar; 10(4):252. PubMed ID: 30874550
[TBL] [Abstract][Full Text] [Related]
24. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
26. Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma.
Gao HY; Wu B; Yan W; Gong ZM; Sun Q; Wang HH; Yang W
Oncol Rep; 2017 Sep; 38(3):1363-1372. PubMed ID: 28713985
[TBL] [Abstract][Full Text] [Related]
27. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
Cao QW; Li HY; Yao XX; Wang JF
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma.
Peng W; Feng J
Biomed Pharmacother; 2016 Feb; 77():65-71. PubMed ID: 26796267
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of long noncoding RNA LEF1-AS1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma.
Zong MZ; Feng WT; Du N; Yu XJ; Yu WY
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7929-7934. PubMed ID: 31599448
[TBL] [Abstract][Full Text] [Related]
30. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
31. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
32. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
[TBL] [Abstract][Full Text] [Related]
33. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
35. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
36. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
37. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
38. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma.
Cho U; Oh WJ; Hong YK; Lee YS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):254-262. PubMed ID: 27490760
[TBL] [Abstract][Full Text] [Related]
40. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R
Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]